Nontuberculous Mycobacterium Infection and Tumor Necrosis Factor-α Antagonists

Swart, Reinout M.; Ingen, Jakko van; Soolingen, Dick van; Slingerland, R.; Hendriks, W. D. H.; Hollander, Jan G. den

doi:10.3201/eid1510.090110

Cited by 21 publications

(15 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cutaneous M. haemophilum has previously been reported after alemtuzumab (an antibody directed against CD52) treatment for B‐cell lymphoma 6 . Pulmonary M. haemophilum has been reported in a woman receiving both adalimumab and methotrexate for rheumatoid arthritis 7 …”

mentioning

confidence: 99%

CutaneousMycobacterium haemophiluminfection in a patient receiving infliximab for psoriasis

Aslam¹,

Green²,

Motta³

et al. 2012

British Journal of Dermatology

View full text Add to dashboard Cite

mentioning

confidence: 99%

CutaneousMycobacterium haemophiluminfection in a patient receiving infliximab for psoriasis

Aslam¹,

Green²,

Motta³

et al. 2012

British Journal of Dermatology

View full text Add to dashboard Cite

“…This low-virulence organism does not cause disease in immunocompetent adults, but does cause disease as an opportunistic pathogen in immunocompromised adults such as those with HIV infection, immunosuppression for organ transplants, those on chemotherapy for malignancy and those on disease modifying antirheumatic drugs such as methotrexate or anti-TNF-α therapy 3 4. These types of immunocompromised patients are thought to be at risk because of impaired cell-mediated immunity and difficulty with granuloma formation and maintenance.…”

Section: Discussionmentioning

confidence: 99%

DisseminatedMycobacterium haemophiluminfection in a 72-year-old patient with rheumatoid arthritis on infliximab

2013

View full text Add to dashboard Cite

Mycobacterium haemophilumis a slow growing, aerobic, fastidious mycobacterium requiring hemin and a temperature of 30–32° C for optimal growth that is ubiquitous in nature. Disease in immunocompromised adults typically manifests as skin lesions such as papules, pustules and ulcerations. This organism also causes lymphadenitis in immunocompetent children. Antitumour necrosis factor-α (anti-TNF-α) therapy with agents such as infliximab, etanercept and adalimumab is increasingly being used for immunosuppression in patients with various autoimmune conditions. These agents are known to place patients at increased risk for tuberculosis and other granulomatous diseases. However, little is known about illness caused byM haemophilumin patients on immunosuppression with anti-TNF-α therapy. We describe a case of disseminatedM haemophilummanifesting as skin lesions in a 72-year-old man with rheumatoid arthritis on infliximab and methotrexate.

show abstract

“…Mycobacterium chelonae RA, spondylarthritis [48,49] Mycobacterium haemophilum RA [50] Mycobacterium szulgai RA [51] Representative case reports are shown in this Furthermore, there are potential limits to the generalization of these results. Although the majority of infections occurred with infliximab, this probably represents the more widespread use of this agent compared with etanercept or adalimumab.…”

Section: Adalimumabmentioning

confidence: 99%